Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,366
datasets available to search
ShareScore release 0.9.0
Dataset results
2,366 results for “Grade”
Adult grade II astrocytomas are genetically distinct from their pediatric counterparts, and display a more stem cell-like expression pattern linked with more aggressive behaviour
GEO Series GSE23869. Homo sapiens. 31 samples. Type: Genome variation profiling by genome tiling array; Expression profiling by array.
The Tec kinase ITK optimizes differential NFAT, NF-κB, and Erk1/2 signaling to regulate graded gene induction in mouse CD8+ T cells [ATAC-seq]
GEO Series GSE167302. Mus musculus. 32 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Single-cell RNA Sequencing of pediatric high-grade gliomas
For more information, including a more complete description, data generator contact information, and reference, please see: https://scpca.alexslemonade.org/projects/SCPCP000001.
MR Imaging of Pediatric Subjects with High-Grade Gliomas (DFCI-BCH-BWH-PEDs-HGG 2023)
Pediatric tumors of the central nervous system are the most common cause of cancer-related death in children. The five-year survival rate for high-grade gliomas in children is less than 20%. Due to their rarity, the diagnosis of these entities is often delayed, their treatment is mainly based on historic treatment concepts, and clinical trials require multi-institutional collaborations. The BraTS-PEDs 2023 challenge brings together clinicians and AI/imaging scientists to lead to faster development of automated segmentation techniques that could benefit clinical trials, and ultimately the care of children with brain tumors. The DFCI-BCH-BWH-PEDs-HGG 2023 dataset is a subset of the BraTS-PEDs 2023 challenge as described in this manuscript. The DFCI-BCH-BWH-PEDs-HGG 2023 dataset includes a retrospective multi-institutional cohort of conventional/structural magnetic resonance imaging (MRI) sequences, including pre- and post-gadolinium T1-weighted (labeled as T1 and T1CE), T2-weighted (T2), and T2-weighted fluid-attenuated inversion recovery (T2-FLAIR) images, from Boston's Children Hospital and Dana-Farber Cancer Institute, and Brigham and Women's Hospital (n=61).
Low-Grade Gliomas UCSF
Whole exome sequencing of 23 grade II glioma tumor/normal pairs. The cases here are only those under the age of 40 years old.
Genomic Analysis of Pediatric Low Grade Gliomas
Pediatric low-grade gliomas (PLGGs) are among the most common solid tumors in children but, apart from mutations or duplications in the BRAF kinase in specific subclasses, few genetic driver events are known. Diffuse PLGGs compose a set of uncommon subtypes that exhibit invasive growth and are therefore especially challenging clinically. These tumors are particularly poorly understood. We performed high-resolution copy-number analysis of 44 diffuse PLGGs to identify recurrent alterations. Diffuse PLGGs exhibited fewer such alterations than adult low-grade gliomas, but we identified several significantly recurrent events. The most significant event, 8q13.1 gains, was observed in 28% of diffuse astrocytoma WHO grade II (DA2) and resulted in partial duplication of the transcription factor MYBL1 with truncation of its C-terminal negative-regulatory domain. A similar recurrent deletion-truncation breakpoint was identified in two angiocentric gliomas in the related gene MYB on 6q23.3. Whole genome sequencing of a MYBL1-rearranged diffuse astrocytoma grade II demonstrated MYBL1 tandem duplication and few other events. Two truncated MYBL1 transcripts identified in this tumor induced anchorage-independent growth when expressed in 3T3 cells and tumor formation in nude mice. Truncated transcripts were also expressed in two additional tumors with MYBL1 partial duplication. Our results define clinically relevant molecular subclasses of diffuse PLGGs and highlight a potential role for the MYB family in the biology of low-grade gliomas.
Dataset related to article "Pancreatic Neuroendocrine Tumours: The Role of Endoscopic Ultrasound Biopsy in Diagnosis and Grading Based on the WHO 2017 Classification."
<p>One of the controversial issues in the diagnosis of pancreatic neuroendocrine tumours (pNETs) is the accurate prediction of their clinical behaviour.</p> <p>OBJECTIVES:</p> <p>The aim of the study was to evaluate the role of endoscopic ultrasound (EUS) biopsy in the diagnosis and grading of pNETs in a certified ENETS Center.</p> <p>METHODS:</p> <p>A prospectively maintained database of EUS biopsy procedures was retrospectively reviewed to identify all consecutive patients referred to a certified ENETS Center with a suspicion of pNET between June 2014 and April 2017. The cytological and/or histological specimens were stained and the Ki-67 labeling index was evaluated. In patients undergoing surgery, the grade obtained with EUS-guided biopsy was compared with the final histological grade. The grade was evaluated according to the 2017 WHO classifications and grading.</p> <p>RESULTS:</p> <p>The study population included 59 patients. EUS biopsy material reached an adequacy of 98.3% and was adequate for Ki-67 evaluation in 84.7% of cases. Twenty-nine patients (49.2%) underwent surgery. Of these, 25 patients had Ki-67 evaluated on EUS biopsy: the agreement between EUS biopsy grading and surgical specimen grading was 84%.</p> <p>CONCLUSION:</p> <p>EUS biopsy is an accurate method for the diagnosis and grading of pNETs based on the WHO 2017 Ki-67 labelling scheme.</p>
Link to dataset related to article "FOXA2 controls the cis-regulatory networks of pancreatic cancer cells in a differentiation grade-specific manner."
<p>Differentiation of normal and tumor cells is controlled by regulatory networks enforced by lineage-determining transcription factors (TFs). Among them, TFs such as FOXA1/2 bind naïve chromatin and induce its accessibility, thus establishing new gene regulatory networks. Pancreatic ductal adenocarcinoma (PDAC) is characterized by the coexistence of well- and poorly differentiated cells at all stages of disease. How the transcriptional networks determining such massive cellular heterogeneity are established remains to be determined. We found that FOXA2, a TF controlling pancreas specification, broadly contributed to the cis-regulatory networks of PDACs. Despite being expressed in both well- and poorly differentiated PDAC cells, FOXA2 displayed extensively different genomic distributions and controlled distinct gene expression programs. Grade-specific functions of FOXA2 depended on its partnership with TFs whose expression varied depending on the differentiation grade. These data suggest that FOXA2 contributes to the regulatory networks of heterogeneous PDAC cells via interactions with alternative partner TFs.</p>
Supplementary MRSI Data for "High-Resolution Metabolic Imaging of High-Grade Gliomas using 7T-CRT-FID-MRSI" - NIFTI Format FIXED
<p>Intended as supplementary data to the manuscript "High-Resolution Metabolic Imaging of High-Grade Gliomas using 7T-CRT-FID-MRSI"</p> <p>Authors:<br> Gilbert Hangel, Cornelius Cadrien, Philipp Lazen, Julia Furtner, Alexandra Lipka, Eva Hečková, Lukas Hingerl, Stanislav Motyka, Stephan Gruber, Bernhard Strasser, Barbara Kiesel, Mario Mischkulnig, Matthias Preusser, Thomas Roetzer, Adelheid Wöhrer, Georg Widhalm, Karl Rössler, Siegfried Trattnig and Wolfgang Bogner</p> <p>###################################################<br> MRSI Maps from the Vienna 7T scanner in MINC format<br> ###################################################</p> <p>Contact: wolfgang.bogner@meduniwien.ac.at , gilbert.hangel@meduniwien.ac.at<br> https://hfmr.meduniwien.ac.at/</p> <p>For use with NIFTI-displaying software.</p> <p>MRSI method published as Hingerl et al 2020, doi: 10.1097/RLI.0000000000000626</p> <p>Patient 1:<br> Glioblastoma WHO Grade 4, with IDH1 mutation, male<br> Patient 2:<br> Glioblastoma WHO Grade 4, with IDH1 mutation, male<br> (Same numbers as in the manuscript)</p>
Dataset related to article "Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade"
<p>This report contains raw data related to article "<em>Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade".</em></p> <p>Immune checkpoint inhibitors (ICI) have shown positive results in patients with hepatocellular carcinoma (HCC). As liver function contributes to prognosis, its precise assessment is necessary for the safe prescribing and clinical development of ICI in HCC. We tested the accuracy of the albumin-bilirubin (ALBI) grade as an alternative prognostic biomarker to the Child-Turcotte-Pugh (CTP). In a prospectively maintained multi-centre dataset of HCC patients, we assessed safety and efficacy of ICI across varying levels of liver dysfunction described by CTP (A to C) and ALBI grade and evaluated uni- and multi-variable predictors of overall (OS) and post-immunotherapy survival (PIOS). We studied 341 patients treated with programmed-death pathway inhibitors (<em>n</em> = 290, 85%). Pre-treatment ALBI independently predicted for OS, with median OS of 22.5, 9.6, and 4.6 months across grades (<em>p</em> < 0.001). ALBI was superior to CTP in predicting 90-days mortality with area under the curve values of 0.65 (95% CI 0.57-0.74) versus 0.63 (95% CI 0.54-0.72). ALBI grade at ICI cessation independently predicted for PIOS (<em>p</em> < 0.001). Following adjustment for ICI regimen, neither ALBI nor CTP predicted for overall response rates or treatment-emerging adverse events (<em>p</em> > 0.05). ALBI grade identifies a subset of patients with prolonged survival prior to and after ICI therapy, lending itself as an optimal stratifying biomarker to optimise sequencing of systemic therapies in advanced HCC.</p>
Glioma - Human Leukocyte Antigen Tissue Microarray. Data from: Deep Learning Glioma Grading with the Tumor Microenvironment Analysis Protocol for Comprehensive Learning, Discovering, and Quantifying Microenvironmental Features
<p>This repository contains images of Human Leukocyte Antigen Stained Tissue Microarray used for the experiments in the manuscript: Pytlarz, M., Wojnicki, K., Pilanc, P. et al. Deep Learning Glioma Grading with the Tumor Microenvironment Analysis Protocol for Comprehensive Learning, Discovering, and Quantifying Microenvironmental Features. J Digit Imaging. Inform. med. (2024). https://doi.org/10.1007/s10278-024-01008-x <br><br>Please cite this paper in case of using the data or methods described in it. <br>Data is shared for scientific research purposes only. Users must not take any actions that could compromise the privacy of the data.</p>
Dataset related to article "Long term follow up in 183 high grade meningioma: A single institutional experience"
<p>Database contains epidemiological, diagnostic, therapeutic, recurrence information and survival data of HGM treated at our institution between 2010 and 2018.</p>
Link to dataset related to article "Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer-Current Use and Future Opportunities "
<p>This record contains raw data related to article “"Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer-Current Use and Future Opportunities"</p> <p>The lack of a sensitive and specific biomarker and the limits relating to the single primary tumor sampling make it difficult to monitor high-grade serous epithelial ovarian cancer (HGS-EOC) over time and to capture those alterations that are potentially useful in guiding clinical decisions. To overcome these issues, liquid biopsy has emerged as a very promising tool for HGS-EOC. The analysis of circulating tumor DNA appears to be feasible and studies assessing specific pathogenic mutations (i.e., <em>TP53</em>) or copy number alterations have shown a sufficient degree of sensitivity and specificity to be realistically used to monitor the effectiveness of antitumor therapy. Liquid biopsy can also provide potential important information on the mechanisms of sensitivity and resistance, e.g., by the determination of the reversion of <em>BRCA</em> mutations. Perspective studies are needed to test whether the application of liquid biopsy will significantly improve HGS-EOC management and patients' survival.</p> <p> </p>
Dataset related to article "Re-irradiation for recurrent high grade glioma (HGG) patients: Results of a single arm prospective phase 2 study"
<p>This record contains raw data related to article “Re-irradiation for recurrent high grade glioma (HGG) patients: Results of a single arm prospective phase 2 study"</p> <p><strong>Background and purpose: </strong> Standard of care for recurrent high grade glioma (HGG) is missing. Several treatment options have been investigated including re-irradiation (re-RT). Results are promising but provided by retrospective studies. We designed a single arm prospective phase II study aiming to evaluate efficacy, and toxicity of re-irradiation.</p> <p><strong>Materials and methods: </strong> Adults patients with good performance status, HGG diagnosis reclassified according to the new 2021 fifth edition WHO CNS classification, an interval time (IT) from previous RT ≥ 6 months were included. Outcome was evaluated by MRI imaging at 1 month, and every 3 months thereafter. Toxicities were evaluated in terms of radionecrosis occurrence, and neurocognitive status.</p> <p><strong>Results: </strong> Ninety recurrent HGG patients were treated, 11 oligodendroglioma grade 3, 18 astrocytoma grade 3 and 4, and 61 glioblastoma grade 4. The median age was 54 years, and majority had KPS 90-100. The median IT between first-RT and re-RT was 24 months. Re-surgery has been performed in 56.6%, and chemotherapy in 53.3%. The median follow up time was 64 months; median overall survival (OS) time,1,2,3-year OS rates were 17 months (95%CI 14-19), 66.7%±4.9, 32.6%±5.0, and 22.2 ± 4.7. Prognostic factors impacting on survival were age (p = 0.0154), IT between first RT and re-RT (p = 0.0051), glioma grade (p = 0.0090), and IDH status (p = 0.0001). Radionecrosis grade 2-3 occurred in 9 (10%) patients; neurocognitive functions remained stable until disease progression.</p> <p><strong>Conclusion: </strong> Re-RT proved to be a safe and feasible treatment option with low toxicity. Younger patients with grade 3 IDH mutated gliomas, and a longer IT had the better outcome.</p>
Dataset related to article "Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas"
<p>This record contains data related to article "Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas"</p> <p><strong>Background: </strong> PET with radiolabelled amino acids is used in the preoperative evaluation of patients with glial neoplasms. This study aimed to assess the role of [ 11C]methionine (MET) PET in assessing molecular features, tumour extent, and prognosis in newly-diagnosed lower-grade gliomas (LGGs) surgically treated.</p> <p><strong>Methods: </strong> 153 patients with a new diagnosis of grade 2/3 glioma who underwent surgery at our Institution and were imaged preoperatively using [ 11C]MET PET/CT were retrospectively included. [ 11C]MET PET images were qualitatively and semiquantitatively analyzed using tumour-to-background ratio (TBR). Progression-free survival (PFS) rates were estimated using the Kaplan-Meier method and Cox proportional-hazards regression was used to test the association of clinicopathological and imaging data to PFS.</p> <p><strong>Results: </strong> Overall, 111 lesions (73%) were positive, while thirty-two (21%) and ten (6%) were isometabolic and hypometabolic at [ 11C]MET PET, respectively. [ 11C]MET uptake was more common in oligodendrogliomas than IDH-mutant astrocytomas (87% vs 50% of cases, respectively). Among [ 11C]MET-positive gliomas, grade 3 oligodendrogliomas had the highest median TBRmax (3.22). In 25% of patients, PET helped to better delineate tumour margins compared to MRI only. In IDH-mutant astrocytomas, higher TBRmax values at [ 11C]MET PET were independent predictors of shorter PFS.</p> <p><strong>Conclusions: </strong> This work highlights the role of preoperative [ 11C]MET PET in estimating the type, assessing tumour extent, and predicting biological behaviour and prognosis of LGGs. Our findings support the implementation of [ 11C]MET PET in routine clinical practice to better manage these neoplasms.</p> <p> </p>
Dataset related to article "Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer"
<p>This record contains raw data related to article<strong> "</strong>Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer<strong>".</strong></p> <p>We have previously demonstrated that longitudinal untargeted analysis of plasma samples withdrawn from patients with high-grade serous ovarian cancer (HGS-EOC) can intercept the presence of molecular recurrence (TRm) earlier than the diagnosis of clinical recurrence (TRc). This finding opens a clinical important temporal window to acquire through plasma sample analysis a real-time picture of those emerging molecular lesions that will drive and sustain the growth of relapsed disease and ultimately will confer resistance. In this proof of principle study, the same genomic libraries obtained at the diagnosis (T0), TRm and TRc were further analyzed by targeted resequencing approach to sequence the coding region of a panel of 65 genes to provide longitudinal analysis of clonal evolution as a novel strategy to support clinical decisions for the second-line treatment. Experiments were performed on plasma and tumor tissues withdrawn on a selection of previously analyzed cohorts of cases (i.e., 33 matched primary and synchronous lesions and 43 plasma samples from 18 patients). At T0, the median concordance of mutations shared by each tumor tissue biopsy and its matched plasma sample was 2.27%. This finding confirms the limit of a single tumor biopsy to be representative of the entire disease, while plasma analysis can recapitulate most of the main molecular lesions of the disease. A comparable scenario was observed during longitudinal analysis, where, with the exception of the <em>TP53</em> gene and germline mutations in <em>BRCA1/2</em> genes, no other gene shared the same locus specific gene mutation across T0, TRm and TRc time points. This high level of temporal heterogeneity has important implications for planning second-line treatment. For example, in three out of 13 cases, plasma ctDNA analysis at TRm or TRc reported acquired novel variants in the <em>TP53BP1</em> gene not present at T0. In particular, patient 21564, potentially eligible for PARP-inhibitor (PARPi) treatment at the time of diagnosis (<em>BRCA1</em> c.5182delA mutation), would unlikely respond to these drugs in second-line therapy due to the presence of eight distinct <em>TP53BP1</em> variants in plasma samples collected TRc. This study demonstrates that liquid biopsy provides a real-time molecular picture to intercept those actionable genetic vulnerabilities or drug resistance mechanisms that could be used to plan a more rational second-line treatment.</p>
Direct Isotopic Analysis of Nuclear-Grade Boron Carbide Using Calibration-Free Laser Ablation Molecular Isotopic Spectrometry (CF-LAMIS)
<p>The dataset provided contains measurements for the article "Direct Isotopic Analysis of Nuclear-Grade Boron Carbide Using Calibration-Free Laser Ablation Molecular Isotopic Spectrometry (CF-LAMIS)"</p>
Single-Cell RNA-seq Reveals FGF12 as a Prognostic Biomarker in Low-Grade Endometrial Stromal Sarcoma
<p><strong><span>Abstract </span></strong></p> <p><strong><span>Background: </span></strong><span>Low-grade endometrial stromal sarcoma (LG-ESS) is a rare uterine malignancy characterized by its complex tumor microenvironment (TME) and significant recurrence rates, posing challenges in accurate prognosis and effective treatment. Identifying prognostic biomarkers is essential to improve patient stratification and guide therapeutic strategies.</span></p> <p><span> </span></p> <p><strong><span>Methods: </span></strong><span>Using single-cell transcriptome analysis combined with H&E and multiplex immunofluorescence staining, we identified a subpopulation of tumor cells in LG-ESS and further validated the association of this subpopulation and its characteristic genes with LG-ESS prognosis by molecular characterization and bulk transcriptome data.</span></p> <p><span> </span></p> <p><strong><span>Results: </span></strong><span>Our analysis reveals multiple cellular subpopulations within the tumor tissue, particularly a tumor cell subpopulation among them which is associated with poor prognosis. Originating from normal stromal fibroblasts, this subpopulation appears to play a crucial role in TME remodeling, smooth muscle cell behavior, and potentially in tumorigenesis and metastasis. At particular interest in this subpopulation is the highly expressed FGF12 gene, which is significantly associated with a shortened survival time of ESS, highlighting its potential as a prognostic biomarker.</span></p> <p><span> </span></p> <p><strong><span>Conclusion: </span></strong><span>Our study reveals the complexity of TME within the LG-ESS and highlights the role that tumor cell subpopulations play in disease progression and patient prognosis. The identification of FGF12 as prognostic biomarkers suggests new approach for the personalized treatment and prognosis monitoring of patients. </span></p>
Data set for Sinhala Textbook Summarization (Grade 6)
<p>This data set was derived to fine-tune GPT-3 models, to support auto-summarization in Sinhala.</p> <p> </p> <p>The attached datasets were validated by School experts (teachers with more than 10 years of teaching experience in the Sinhala Language for grade 6 students)</p>
DATASET RELATED TO ARTICLE "MONOALLELIC AND BIALLELIC MUTATIONS IN RELN UNDERLIE A GRADED SERIES OF NEURODEVELOPMENTAL DISORDERS
<p>clinical data of a single RELN case patient followed at Fondazione Besta involved in the study at title</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.